INTRODUCTION Lung cancer is the leading cause of cancer-related mortality. Platinum-based chemotherapy is the usual first-line treatment for advanced nonsmall cell lung cancer (NSCLC), although an efficacy plateau has been reached with this approach. Bevacizumab is a recombinant, humanized, monoclonal antibody to vascular endothelial growth factor, which inhibits tumor angiogenesis and is being...

Vaccines that rely on active specific stimulation of the host immune system have the potential to trigger durable antitumor responses with minimal toxicity. However, in nonsmall-cell lung cancer (NSCLC), several large phase III trials of vaccines reported within the last year have yielded disappointing results. Compared with placebo, belagenpumatucel-L (an allogenic tumor cell vaccine), tecemot...

Background Drug resistance is a major concern in the current chemotherapeutic approaches and the combination with natural compounds may enhance the cytotoxic effects of the anticancer drugs. Therefore, this study evaluated the cytotoxicity of crude ethyl extracts of six marine-derived fungi - Neosartorya tsunodae KUFC 9213 (E1), Neosartorya laciniosa KUFC 7896 (E2), Neosartorya fischeri KUFC 63...

The recently discovered long noncoding RNAs have the potential to regulate many biological processes, which are aberrantly expressed in many tumor types. Our previous study showed that the long noncoding RNA-growth arrest-specific transcript 5 (GAS5) was decreased in lung cancer tissue, which contributed to the proliferation and apoptosis of nonsmall cell lung cancer (NSCLC). GAS5 was also asso...

Background: Patients with non-small cell lung cancer (NSCLC) harboring anaplastic lymphoma kinase (ALK) fusions may benefit from ALK-tyrosine inhibitors (ALK-TKIs). However, few studies have analyzed the clinical outcome in patients multiple ALK fusions, including double or triple fusions. Here, our study aimed to analyze impact of on efficacy receiving ALK-TKIs NSCLC patients.

Introduction: Lung cancer is the leading cause of cancer-related mortality. Platinum-based chemotherapy is the usual first-line treatment for advanced nonsmall cell lung cancer (NSCLC), although an efficacy plateau has been reached with this approach. Bevacizumab is a recombinant, humanized, monoclonal antibody to vascular endothelial growth factor, which inhibits tumor angiogenesis and is bein...

MicroRNAs (miRNAs) are a class of small, noncoding RNA molecules involved in carcinogenesis. It has been identified that genetic variations in miRNAs contribute to cancer risk, prognosis, and survival. In the present study, we investigated whether single nucleotide polymorphisms (SNPs) of several key miRNAs (miR-184, miR-218, and miR-124) were associated with the prognosis of nonsmall cell lung...

Selpercatinib, a first-in-class, highly selective and potent inhibitor of the rearranged during transfection (RET) kinase with central nervous system (CNS) activity, is approved in multiple countries for use RET fusion-positive non-small cell lung cancer (NSCLC) RET-altered thyroid cancers. Herein, we present results from LIBRETTO-321 (NCT04280081), first study to evaluate efficacy safety selpe...

Lung Cancer is the leading cause of cancer-related death in the United States; yet despite this fact, common misconceptions hinder progress towards a better understanding of this fatal carcinoma. It is divided into two crudely differentiated sub-types which are distinguished by the appearance of their respective cells under a microscope: Small-Cell (SCLC) and Non-Small-Cell Lung Carcinomas (NSC...

Combination of epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) with platinumcontaining standard chemotherapy failed to provide better outcomes in the first-line setting for advanced nonsmall cell lung cancer (NSCLC) in several phase III trials. The approved monotherapy of erlotinib, pemetrexed or docetaxel as the second-line regimen still remains unsatisfactory in anti-tum...